[REVISION HISTORY]

Iovance Biotherapeutics financial performance and stock rise

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-08-15 20:52 UTC → 2026-08-17 08:06 UTC · added ~~removed~~

Iovance Biotherapeutics experienced significant financial growth and stock market momentum in mid-2026. The company reported second-quarter revenue of approximately $99.3 million, representing a 66% increase from the previous year and exceeding analyst expectations. This growth was largely attributed to $91 million in U.S. sales of its cell therapy, Amtagvi, for advanced melanoma. Following these results, the company’s stock saw an initial surge of over 30%. By mid-August, the shares had rallied more than 130% year-to-date, approaching 52-week highs. While technical indicators showed a strong bullish trend with prices remaining above key moving averages, analysis also noted the stock might be in overbought territory due to a high Relative Strength Index. By August 15, 2026, the stock reached a 52-week high, closing at $6.98. This rally followed record revenue for Amtagvi and improved gross margins in the second quarter. Despite the upward momentum, technical indicators such as the RSI continued to suggest overbought conditions.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.